In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog PN-943 | Synthetic analog Teduglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Gut and digestion | Gut and digestion | |
| Evidence | |||
| Amount of evidence | 13 | 362 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 1 (1 in people) | 73 (73 in people) | |
| Status | |||
| Approval | Not recorded | ||
| Sport (WADA) | |||
| Registered trials | 1 | 46 · 4 active4 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | PN-943 | Teduglutide |
|---|---|---|
| Adverse eventsWhole body | 11 | 5050 |
| PharmacokineticsPharmacology |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Gattex says: “Adults and pediatric patients 1 year of age and older with short bowel syndrome who depend on parenteral support”
99
17134 |
| Receptor activity and mechanismPharmacology | 33 | 1212 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)
Protagonist Therapeutics, Inc.169 participants5 Aug 2020 to 16 Feb 2023
Ulcerative Colitis Chronic Moderate · Ulcerative Colitis Chronic Severe
Top 3 of 46 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Shire88 participants21 Sept 2009 to 24 Jan 2013
Short Bowel Syndrome
Shire86 participants25 Nov 2008 to 25 Jan 2011
Short Bowel Syndrome
Shire84 participants25 May 2004 to 6 Jul 2007
Short Bowel Syndrome
4 more mention it but do not test it. They only measure it or name it in their text.